GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Cash Conversion Cycle

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Cash Conversion Cycle : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Sichuan Kelun-Biotech Biopharmaceutical Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.
Sichuan Kelun-Biotech Biopharmaceutical Co's Days Inventory for the three months ended in Dec. 2023 was 0.
Sichuan Kelun-Biotech Biopharmaceutical Co's Days Payable for the three months ended in Dec. 2023 was 0.
Therefore, Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 0.00.


Sichuan Kelun-Biotech Biopharmaceutical Co Cash Conversion Cycle Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Cash Conversion Cycle Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Cash Conversion Cycle
-1,443.39 -123.54 -98.19

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial - -79.66 -74.55 - -

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle falls into.



Sichuan Kelun-Biotech Biopharmaceutical Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+27.28-125.47
=-98.19

Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Sichuan Kelun-Biotech Biopharmaceutical Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines